Melatonin decreases human adipose tissue insulin sensitivity
Metadatos
Mostrar el registro completo del ítemAutor
Zambrano, Carolina; Tena Garitaonaindia, Mireia; Salmerón, Diego; Pérez Sanz, Fernando; Tchio, Cynthia; Picinato, María Cecilia; Sánchez De Medina López-Huertas, Fermín; Luján, Juan; A. J. L. Scheer, Frank; Saxena, Richa; Martínez Augustin, Olga; Garaulet, MartaEditorial
Wiley Online Library
Materia
adipose tissue explants insulin sensitivity
Fecha
2024-06-11Referencia bibliográfica
Zambrano, C. et. al. J Pineal Res. 2024;76:e12965. [https://doi.org/10.1111/jpi.12965]
Patrocinador
Grant PID2020‐ 112768RB‐I00 funded by MCIN/AEI/10.13039/ 501100011033; The Spanish Government of Investigation, Development and Innovation (PID2020‐120140RB‐I00 OMA) including FEDER; Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain (PI21/00952), cofunded by European Regional Development Fund/ European Social Fund; Autonomous Community Junta de Andalucía [A‐AGR‐468‐UGR20 and P20‐00695, CTS235, CTS164]; NIDDK R01DK105072; NIDDK R01DK105072 and NHLBI R01HL140574; Ministry of Education [Spain]; CIBERehd is funded by Instituto de Salud Carlos IIIResumen
Melatonin is a pineal hormone that modulates the circadian system and exerts
soporific and phase‐shifting effects. It is also involved in many other
physiological processes, such as those implicated in cardiovascular, endocrine,
immune, and metabolic functions. However, the role of melatonin in glucose
metabolism remains contradictory, and its action on human adipose tissue
(AT) explants has not been demonstrated. We aimed to assess whether
melatonin (a pharmacological dose) influences insulin sensitivity in human
AT. This will help better understand melatonin administration's effect on
glucose metabolism. Abdominal AT (subcutaneous and visceral) biopsies were obtained from 19 participants with severe obesity (age: 42.84 ± 12.48 years;
body mass index: 43.14 ± 8.26 kg/m2) who underwent a laparoscopic gastric
bypass. AT biopsies were exposed to four different treatments: control (C),
insulin alone (I) (10 nM), melatonin alone (M) (5000 pg/mL), and insulin plus
melatonin combined (I + M). All four conditions were repeated in both
subcutaneous and visceral AT, and all were performed in the morning at
8 a.m. (n = 19) and the evening at 8 p.m. (in a subsample of n = 12). We used
western blot analysis to determine insulin signaling (using the pAKT/
tAKT ratio). Furthermore, RNAseq analyses were performed to better
understand the metabolic pathways involved in the effect of melatonin on
insulin signaling. As expected, insulin treatment (I) increased the pAKT/
tAKT ratio compared with control (p < .0001). Furthermore, the addition of
melatonin (I +M) resulted in a decrease in insulin signaling as compared with
insulin alone (I); this effect was significant only during the evening time (not
in the morning time). Further, RNAseq analyses in visceral AT during the
evening condition (at 8 p.m.) showed that melatonin resulted in a prompt
transcriptome response (around 1 h after melatonin addition), particularly by
downregulating the insulin signaling pathway. Our results show that
melatonin reduces insulin sensitivity in human AT during the evening. These
results may partly explain the previous studies showing a decrease in glucose
tolerance after oral melatonin administration in the evening or when eating
late when endogenous melatonin is present.